Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02686047
Previous Study | Return to List | Next Study

Comparing One Intraarticular Injection of a Novel HYAJOINT Plus With Synvisc-One for the Treatment of Knee OA

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02686047
Recruitment Status : Completed
First Posted : February 19, 2016
Last Update Posted : February 19, 2016
Sponsor:
Information provided by (Responsible Party):
Shu-Fen Sun, Kaohsiung Veterans General Hospital.

Brief Summary:
Viscosupplementation has been widely used for the treatment of knee osteoarthritis (OA). There is no well controlled trial comparing one injection regimen of HA for the treatment of knee OA. The purpose of this study was to compare the efficacy and safety of one intraarticular injection of a novel crosslinked HA (HYAJOINT Plus) with Synvisc-One for the treatment of knee OA.

Condition or disease Intervention/treatment Phase
Knee Osteoarthritis Device: HYAJOINT Plus Device: Synvisc-One Phase 2 Phase 3

Detailed Description:
In a prospective, randomized controlled, double-blind trial with 6-month follow up, patients with knee OA (Kellgren-Lawrence grade 2 or 3) were randomized to receive one intraarticular injection of 3 ml HYAJOINT Plus (microbial fermented HA, 20 mg/ml) (N=66) or 6 ml Synvisc-One (avian derived HA, 8 mg/ml) (N=66). The primary outcome was change in the visual analog scale (VAS) pain (0-100mm) over 6 months. Secondary outcomes included The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Lequesne index, Timed Up-and-Go test (TUG), single leg stance test (SLS), use of rescue analgesics and patient satisfaction.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 132 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Comparing Efficacy and Safety of a Single Intraarticular Injection of a Novel Crosslinked Hyaluronic Acid (HYAJOINT Plus) With Synvisc-One for the Treatment of Knee Osteoarthritis: A Randomized-Controlled, Double-Blind Trial
Study Start Date : September 2014
Actual Primary Completion Date : August 2015
Actual Study Completion Date : August 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Arm Intervention/treatment
Experimental: the HYAJOINT Plus group
the HYAJOINT Plus group received one intraarticular injection of 3 ml HYAJOINT Plus (2% microbial fermented HA, 20 mg/ml).
Device: HYAJOINT Plus
The patients in the HYAJOINT Plus group received one intraarticular injection of 3 ml HYAJOINT Plus (2% microbial fermented HA, 20 mg/ml).
Other Name: Hyaluronic acid

Active Comparator: The Synvisc-One group
The Synvisc-One group received one injection of 6 ml Synvisc-One (0.8% avian derived HA, 8 mg/ml).
Device: Synvisc-One
The Synvisc-One group received one injection of 6 ml Synvisc-One (0.8% avian derived HA, 8 mg/ml).




Primary Outcome Measures :
  1. VAS pain score [ Time Frame: at 1, 3 and 6 months postinjection ]
    the change from baseline in the VAS pain score over 6 months.


Secondary Outcome Measures :
  1. WOMAC, Likert Scale [ Time Frame: at 1, 3 and 6 months postinjection ]
    a 24-item questionnaire with 3 subscales measuring pain, stiffness, and physical function. Total score is 96 and lower scores indicate better outcomes.

  2. Lequesne index [ Time Frame: at 1, 3 and 6 months postinjection ]
    Maximal score is 24 and higher scores represent worse function.

  3. Timed Up-and-Go test (TUG) [ Time Frame: at 1, 3 and 6 months postinjection ]
    a simple measurement of time in seconds for a person to rise from an armchair, walk 3 meters, turn around, walk back to the chair, and sit down

  4. Single-leg stance test (SLS) [ Time Frame: at 1, 3 and 6 months postinjection ]
    by raising one foot up without touching it to the supported lower extremity with target knee OA and maintain balance for as long as possible.

  5. satisfaction based on a 100 mm VAS [ Time Frame: at 1, 3 and 6 months postinjection ]
    Patients were asked to rate their treatment satisfaction compared to the preinjection condition, based on a 100 mm VAS

  6. The reported adverse events [ Time Frame: at 1 week (safety records via phone call), 1, 3 and 6 months after the injection ]
    based on adverse events reported by the patients during the study period and physical examination findings by the evaluator after injections and at each follow-up visit



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • symptomatic knee OA with pain for at least 6 months, despite conservative treatment such as analgesics, NSAIDs and/or physical therapy
  • average pain on knee movement of 30 mm or greater on a 100-mm VAS

    • grade 2 or 3 knee OA according to the Kellgren-Lawrence grading system based on radiographs taken within the previous 6 months
    • Radiological evidence of bilateral knee OA was accepted if global pain VAS in the contralateral knee was less than 30 mm.

Exclusion Criteria:

  • previous orthopedic surgery on the spine or lower limbs
  • disabling OA of either hip or foot
  • knee instability, clinical apparent joint effusion or marked valgus/varus deformity
  • known allergy to avian proteins or HA products
  • women ascertained or suspected pregnancy or lactating
  • intraarticular injections within the past 6 months
  • infections or skin diseases around the target knee
  • any specific medical conditions (rheumatoid arthritis, hemiparesis, neoplasm, etc.) that would interfere with the assessments

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02686047


Locations
Layout table for location information
Taiwan
Kaohsiung Veterans General Hospital
Kaohsiung, Taiwan, 813
Sponsors and Collaborators
Kaohsiung Veterans General Hospital.

Layout table for additonal information
Responsible Party: Shu-Fen Sun, MD, Kaohsiung Veterans General Hospital.
ClinicalTrials.gov Identifier: NCT02686047     History of Changes
Other Study ID Numbers: VGHKS14-CT8-12
First Posted: February 19, 2016    Key Record Dates
Last Update Posted: February 19, 2016
Last Verified: February 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Shu-Fen Sun, Kaohsiung Veterans General Hospital.:
Knee osteoarthritis
Hyaluronic acid
Viscosupplementation
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis
Osteoarthritis, Knee
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Hyaluronic Acid
Hylan
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Viscosupplements
Protective Agents